Results 201 to 210 of about 93,838 (303)

Substrate and effector specificity of a guanosine 3':5'-monophosphate phosphodiesterase from rat liver.

, 1977
Joel Moss, Vincent C. Manganiello, M Vaughan   +2 more
openalex   +1 more source

Use of semaglutide and risk of non‐arteritic anterior ischemic optic neuropathy: A Danish–Norwegian cohort study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To investigate the putative association between semaglutide and non‐arteritic anterior ischaemic optic neuropathy (NAION). Materials and Methods Data from national health registries in Denmark (2018–2024) and Norway (2018–2022) were used to compare NAION risk in individuals with type 2 diabetes initiating semaglutide versus sodium‐glucose
Emma Simonsen, Lars Christian Lund, Martin Thomsen Ernst, Vidar Hjellvik, Laszlo Hegedüs, Steffen Hamann, Øystein Kalsnes Jørstad, Hanne Løvdal Gulseth, Øystein Karlstad, Anton Pottegård   +9 more
wiley   +1 more source

Treatment Approaches for Pulmonary Hypertension in Colombia: A Call to Action. [PDF]

Clin Respir J
Pitsiou GG.
europepmc   +1 more source

Effect of Ca²⁺ on the stability of the protein activator of cyclic nucleotide phosphodiesterase [PDF]

, 1975

openalex   +1 more source

The Complex Spectrum of Chronic Thromboembolic Pulmonary Disease and the Implications of Hemodynamic Reclassification. [PDF]

Ann Am Thorac Soc
Risbano MG.
europepmc   +1 more source

Human placental cAMP phosphodiesterase activity kinetic properties and sensitivity to some drugs and hormones [PDF]

, 1975
F. Ferré, M. Breuiller, L. Cédard
openalex   +1 more source

Atypical MAPKs in cancer

The FEBS Journal, EarlyView.
Mitogen‐activated protein kinases (MAPKs) regulate various cellular processes, including proliferation, differentiation, and motility. Alterations in these signalling pathways can lead to various diseases, including cancer. The atypical MAPKs ERK3 (MAPK6), ERK4 (MAPK4), ERK7/8 (MAPK15) and NLK have long been neglected in kinomic studies.
Katrin Dahm, Parthiban Vijayarangakannan, Hans‐Peter Wollscheid, Hansjörg Schild, Krishnaraj Rajalingam   +4 more
wiley   +1 more source

Phosphodiesterase 4 inhibition as a novel treatment for stroke. [PDF]

PeerJ
Zhong J, Yu X, Lin Z.
europepmc   +1 more source

A comparison of the activity of phosphatidylinositol phosphodiesterase against substrate in dispersions and as monolayers at the air-water interface [PDF]

, 1975
Peter J. Quinn, Y. Barenholz
openalex   +1 more source

Targeted protein degradation of PDE4 shortforms by a novel proteolysis targeting chimera

The FEBS Journal, EarlyView.
Here, we report KTX207, a previously undescribed cereblon‐based PDE4 PROTAC that can specifically target PDE4D shortform for degradation. We showed that KTX207 could improve selectivity, potency and enable a long‐lasting effect when used at a sub‐nanomolar concentration.
Yuan Yan Sin, Aoife Giblin, Aleksandra Judina, Punchita Rujirachaivej, Laura G. Corral, Eliza Glennon, Zhi Xian Tai, Tian Feng, Eduardo Torres, Alina Zorn, Julia Gorelik, Elka Kyurkchieva, Pa Thai Yenchitsomanus, Cathy Swindlehurst, Kyle Chan, David Stirling, George S. Baillie   +16 more
wiley   +1 more source